Quick Answer
Cullinan Therapeutics, Inc. reported Diluted EPS of $3.69 per share (loss) for fiscal year 2023.
Cullinan Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2023 | -$3.69 | -255.0% |
| 2022 | $2.38 | +256.6% |
| 2021 | -$1.52 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2024 | -$0.69 | +24.2% | +8.0% |
| June 30, 2024 | -$0.75 | +8.5% | +12.8% |
| March 31, 2024 | -$0.86 | +39.4% | +5.5% |
| September 30, 2023 | -$0.91 | -68.5% | -11.0% |
| June 30, 2023 | -$0.82 | -121.8% | +42.3% |
| March 31, 2023 | -$1.42 | -425.9% | -163.0% |
| September 30, 2022 | -$0.54 | -35.0% | -114.3% |
| June 30, 2022 | $3.77 | +1147.2% | +1496.3% |
- Cullinan Therapeutics, Inc. showed a decrease of -255.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2023 period, Cullinan Therapeutics, Inc.’s diluted eps has declined by 142.8% (from $1.52 per share (loss) to $3.69 per share (loss)).
- The most recent figure is from Cullinan Therapeutics, Inc.’s fiscal year 2023 report (Form 10-K), filed with the SEC on March 14, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: